What we do
The incidence of diabetes and other endocrinological conditions is rapidly increasing on a global scale.
Endo – Metabolic CRO Expert
There are over 70 million patients diagnosed with Diabetes Type I and II in the countries covered by us.
As health budgets are limited in certain areas, patients have limited access to modern treatments such as insulins, DPP-4 inhibitors and GLP1 agonists, so they are eager to participate in clinical trials.
75 Studies conducted
53% of Phase II and Phase III
3 450+
patients enrolled
Close collaboration with
300+ sites
14 indications in the last 5 years
Optimapharm’s top 5 indications in Endocrine – Metabolic studies
Staff experience
138 staff members with Endocrine – Metabolic projects experience
Factsheet
Case study
Brochure
